Ifm_05-may 2022 Today

One critical finding was an increased risk of developing a second primary malignancy (SPM) while on long-term lenalidomide maintenance. Patient Considerations

To determine if continuous low-dose chemotherapy after a transplant could improve overall survival and keep the disease controlled for longer periods. IFM_05-May 2022

Lenalidomide was the primary drug used for maintenance in this study. Key Findings: One critical finding was an increased risk of

A significant number of patients (roughly 27%) had to stop the maintenance therapy early due to adverse side effects. IFM_05-May 2022

The study demonstrated a clear overall survival benefit for patients receiving maintenance therapy compared to a placebo.

The (often referred to simply as the IFM-05 study) focused on using lenalidomide as a maintenance treatment.